Page 112 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

110 CHAPTER 4 Immunotherapy

[38] M.V.J.L. Blagosklonny, Target for cancer therapy: proliferating cells or stem cells. 20 (3)
(2006) 385.
[39] J. Zhao, Cancer stem cells and chemoresistance: The smartest survives the raid. Phama-
col. Therapeu. 160 (2016) 145–158.
[40] E. Chu, V.T. DeVita Jr., Physicians’ Cancer Chemotherapy Drug Manual 2018, Jones &
Bartlett Learning, (2017).
[41] B. Eichhorst, A.-M. Fink, J. Bahlo, R. Busch, G. Kovacs, C. Maurer, M.J.T.l.o. Sökler,
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine,
cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukae-
mia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial 17
(7) (2016) 928–942.
[42] A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. Von Pawel, M.C.J.T.L.
Dols, Atezolizumab versus docetaxel in patients with previously treated non-small-cell
lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial 389
(10066) (2017) 255–265.
[43] C. Cremolini, F. Loupakis, C. Antoniotti, C. Lupi, E. Sensi, S. Lonardi, A.J.T.L.O.
Zaniboni, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-
line treatment of patients with metastatic colorectal cancer: updated overall survival and
molecular subgroup analyses of the open-label, phase 3 TRIBE study 16 (13) (2015)
1306–1315.
[44] V. Bernstein, S. Ellard, S. Dent, D. Tu, M. Mates, S. Dhesy-Thind, A randomized phase
II study of weekly paclitaxel with or without pelareorep in patients with metastatic
breast cancer: final analysis of Canadian Cancer Trials Group IND. 213. 167(2), (2018),
485–493.
[45] Z. DeFilipp, S. Li, A. El-Jawahri, P. Armand, L. Nayak, N. Wang, Y.B.J.C. Chen, High-
dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem
cell transplantation for patients with primary central nervous system lymphoma in first
complete remission 123 (16) (2017) 3073–3079.
[46] C.J. Ryan, M.R. Smith, K. Fizazi, F. Saad, P.F. Mulders, C.N. Sternberg, E.J.J.T.L.O.
Small, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemother-
apy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final
overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
16 (2) (2015) 152–160.
[47] M. Prieto-Vila, R.-u. Takahashi, W. Usuba, I. Kohama, T.J.I.j.o.m.s. Ochiya, Drug resis-
tance driven by cancer stem cells and their niche. 18 (12) (2017) 2574.
[48] C. Da Silva, F. Rueda, C. Löwik, F. Ossendorp, L.J.J.B. Cruz, Combinatorial prospects of
nano-targeted chemoimmunotherapy. 83 (2016) 308–320.
[49] E. Pérez-Herrero, A.J.E.j.o.p. Fernández-Medarde,& biopharmaceutics. Advanced tar-
geted therapies in cancer: drug nanocarriers, the future of chemotherapy. 93, (2015),
52–79.
[50] B. Coiffier, E. Lepage, J. Brière, R. Herbrecht, H. Tilly, R. Bouabdallah, P.J.N.E.J.o.M.
Gaulard, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly
patients with diffuse large-B-cell lymphoma, New Engl. J. Med. 346 (4) (2002) 235–242.
[51] K. Fischer, J. Bahlo, A.M. Fink, V. Goede, C.D. Herling, P. Cramer, C.J.B. Maurer, Long-
term remissions after FCR chemoimmunotherapy in previously untreated patients with
CLL: updated results of the CLL8 trial, Blood 127 (2) (2016) 208–215.
[52] M. Wang, H.J. Lee, S. Thirumurthi, H.H. Chuang, F.B. Hagemeister, J.R. Westin, & W.
Chen. Chemotherapy-free induction with ibrutinib-rituximab followed by shortened